Latest News
Cure SMA Awards $100,000 Grant to Saravanan Arumugam, PhD, Universidad de Seville
Saravanan Arumugam, PhD, was awarded $100,000 for his research project, “Role of Cytosolic and Mitochondrial Ca2+ in the Pathogenesis of Spinal Muscular Atrophy.” Dr. Arumugam’s basic research grant is one […]
Read More ›Cure SMA Announces Expanded Phase 8 of SMA Industry Collaboration
Cure SMA is pleased to announce the launch of an expanded Phase 8 of our SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership that brings together pharmaceutical companies, […]
Read More ›Congress Examines Ways to Improve Air Travel for People with Disabilities
The air travel challenges of people with disabilities took center-stage this week in Congress through two separate congressional hearings. Cure SMA used the congressional action to once again highlight the […]
Read More ›Cure SMA Welcomes New Care Center Network Site!
We’d like to give a warm welcome to Children’s Hospital Colorado as a newly added Cure SMA Care Center! Thank you to Loree, Ward and Lyza Weisman for your generous […]
Read More ›Cure SMA Awards $75,000 Grant to Lyndsay Murray, PhD, University of Edinburgh
Lyndsay Murray, PhD, was awarded $75,000 for her research project, “Evaluating the impact of sequential versus simultaneous administration of SMN-inducing compounds on motor unit recovery in mouse models of SMA.” […]
Read More ›Biohaven’s Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
This week, Biohaven announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal […]
Read More ›